Switch Therapeutics is an emerging biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science, with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet need. The CASi (Conditionally Activated siRNA) platform, the company’s novel gene knockdown approach, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School and City of Hope. CASi combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity. 

Biotechnology

Research

Switch Therapeutics

Dee Datta

Brandi Simpson

Charles Allerson

Shilpi Mahajan

Anindya Bhattacharya

Maxine Nelson

Clara Tourino

Joonhee Han

Alex Embusch

Marina Kovaliov

Jane Li

Robert Duff

Don Button

Craig Blanchette

Michael Wolfe

The Leadership Team at Switch Therapeutics drives the company’s strategic vision and operational execution in pioneering RNA-based therapeutics. Comprising experts in finance, operations, research, and various scientific disciplines, the team collaborates to advance the CASi platform and oversee the development pipeline, ensuring alignment with regulatory standards and market needs. Their collective expertise fosters innovation and positions the company to address significant unmet medical needs in central nervous system and systemic diseases.

Leadership Team

Research Associates

Research and Development

Leadership Team

About

Team members

Other teams at Switch Therapeutics

Research Associates

Research and Development